CalciMedica (NASDAQ:CALC) Cut to “Strong Sell” at Wall Street Zen

Wall Street Zen cut shares of CalciMedica (NASDAQ:CALC) from a sell rating to a strong sell rating in a research note published on Saturday morning,Wall Street Zen reports.

Other equities research analysts have also recently issued reports about the stock. HC Wainwright reaffirmed a “neutral” rating on shares of CalciMedica in a report on Wednesday, July 29th. Guggenheim started coverage on CalciMedica in a report on Thursday, August 20th. They set a “buy” rating on the stock. Weiss Ratings raised CalciMedica from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 27th. Finally, UBS Group restated a “neutral” rating on shares of CalciMedica in a research report on Thursday, August 13th. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, CalciMedica has a consensus rating of “Hold” and an average target price of $50.00.

CalciMedica Stock Up 1.0%

CalciMedica stock opened at $2.00 on Friday. CalciMedica has a fifty-two week low of $1.87 and a fifty-two week high of $36.00. The company has a debt-to-equity ratio of 1.67, a quick ratio of 5.58 and a current ratio of 5.58. The company has a market capitalization of $13.66 million, a P/E ratio of -0.29 and a beta of 0.83. The stock has a 50-day simple moving average of $3.25 and a 200-day simple moving average of $3.43.

CalciMedica (NASDAQ:CALC) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.42) by $0.97. Equities research analysts expect that CalciMedica will post -5.25 earnings per share for the current year.

Insider Activity at CalciMedica

In other news, Director Fred A. Middleton purchased 49,794 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The stock was purchased at an average cost of $4.00 per share, with a total value of $199,176.00. Following the completion of the acquisition, the director directly owned 212,654 shares of the company’s stock, valued at approximately $850,616. This trade represents a 30.57% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 28.25% of the company’s stock.

Hedge Funds Weigh In On CalciMedica

An institutional investor recently raised its stake in CalciMedica stock. 180 Wealth Advisors LLC raised its holdings in CalciMedica Inc. (NASDAQ:CALC) by 297.2% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 126,500 shares of the company’s stock after acquiring an additional 94,650 shares during the quarter. 180 Wealth Advisors LLC owned 0.80% of CalciMedica worth $68,000 as of its most recent filing with the SEC.

CalciMedica Company Profile

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.